Mostrar el registro sencillo del ítem

dc.contributor.authorGuil-Luna, Silvia
dc.contributor.authorStenvang, Jan
dc.contributor.authorBrünner, Nils
dc.contributor.authorDe Andrés, Francisco Javier
dc.contributor.authorSánchez Céspedes, Raquel
dc.contributor.authorMillán, Yolanda
dc.contributor.authorMartín de las Mulas González-Albo, Juana
dc.date.accessioned2017-12-07T11:28:07Z
dc.date.available2017-12-07T11:28:07Z
dc.date.issued2014
dc.identifier.citationBMC Veterinary Research 10:296 (2014)es_ES
dc.identifier.urihttp://hdl.handle.net/10396/15666
dc.description.abstractBackground: Progesterone receptors play a key role in the development of canine mammary tumours, and recent research has focussed on their possible value as therapeutic targets using antiprogestins. Cloning and sequencing of the progesterone receptor gene has shown that the receptor has two isoforms, A and B, transcribed from a single gene. Experimental studies in human breast cancer suggest that the differential expression of progesterone receptor isoforms has implications for hormone therapy responsiveness. This study examined the effects of the antiprogestin aglepristone on cell proliferation and mRNA expression of progesterone receptor isoforms A and B in mammary carcinomas in dogs treated with 20 mg/Kg of aglepristone (n = 22) or vehicle (n = 5) twice before surgery. Results: Formalin-fixed, paraffin-embedded tissue samples taken before and after treatment were used to analyse total progesterone receptor and both isoforms by RT-qPCR and Ki67 antigen labelling. Both total progesterone receptor and isoform A mRNA expression levels decreased after treatment with aglepristone. Furthermore, a significant decrease in the proliferation index (percentage of Ki67-labelled cells) was observed in progesterone-receptor positive and isoform-A positive tumours in aglepristone-treated dogs. Conclusions: These findings suggest that the antiproliferative effects of aglepristone in canine mammary carcinomas are mediated by progesterone receptor isoform A.es_ES
dc.format.mimetypeapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherBioMed Centrales_ES
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/es/es_ES
dc.subjectCanine mammary carcinomaes_ES
dc.subjectProgesterone receptores_ES
dc.subjectIsoformses_ES
dc.subjectAglepristonees_ES
dc.subjectHormone treatmentes_ES
dc.titleProgesterone receptor isoform A may regulate the effects of neoadjuvant aglepristone in canine mammary carcinomaes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttp://dx.doi.org/10.1186/s12917-014-0296-2es_ES
dc.relation.projectIDGobierno de España. AGL2011-25553es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem